Community-based type 2 diabetes care by lay village health workers in rural Lesotho: protocol for a cluster-randomized trial within the ComBaCaL cohort study (ComBaCaL T2D TwiC).
Clinical decision support system
Community health worker
Community-based care
Lesotho
Non-communicable diseases
Sub-Saharan Africa
Type 2 diabetes
Village health workers
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
received:
15
08
2023
accepted:
12
10
2023
medline:
26
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Type 2 diabetes (T2D) poses a growing public health burden, especially in low- and middle-income countries (LMICs). Task-shifting to lay village health workers (VHWs) and the use of digital clinical decision support systems (CDSS) are promising approaches to tackle the current T2D care gap in LMICs. However, evidence on the effectiveness of lay worker-led T2D care models, in which VHWs initiate and monitor drug treatment in addition to community-based screening and referral services, is lacking. We are conducting a cluster-randomized trial nested within the Community-Based Chronic Disease Care Lesotho (ComBaCaL) cohort study (NCT05596773) using the trial within cohort (TwiC) design to assess the effectiveness of a VHW-led, CDSS-assisted T2D care model in rural Lesotho. Participants are non-pregnant members of the ComBaCaL cohort study with T2D. The ComBaCaL cohort study is conducted in approximately 100 villages in two rural districts in Lesotho and is managed by trained and supervised VHWs. In intervention villages, VHWs offer a community-based T2D care package including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS to participants who are clinically eligible, as well as treatment support to participants who prefer or clinically require facility-based T2D care. In control clusters, all participants will be referred to a health facility for T2D management. The primary endpoint is the mean glycosylated haemoglobin (HbA1c) 12 months after enrolment. Secondary endpoints include the 10-year risk for cardiovascular events estimated using the World Health Organization risk prediction tool. The trial was launched on May 13, 2023, and has enrolled 226 participants at the date of submission (October 6, 2023). To our knowledge, the trial is the first to assess task-shifting of T2D care to VHWs at the community level, including the prescription of first-line antidiabetic, lipid-lowering, and antiplatelet medication in sub-Saharan Africa, and will thus provide the missing evidence on the effectiveness of such a T2D care model in this setting. The study is operating within the established Lesotho VHW programme. Similar community health worker programmes which exist across sub-Saharan Africa may benefit from the findings. ClinicalTrials.gov NCT05743387. Registered on February 24 2023.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes (T2D) poses a growing public health burden, especially in low- and middle-income countries (LMICs). Task-shifting to lay village health workers (VHWs) and the use of digital clinical decision support systems (CDSS) are promising approaches to tackle the current T2D care gap in LMICs. However, evidence on the effectiveness of lay worker-led T2D care models, in which VHWs initiate and monitor drug treatment in addition to community-based screening and referral services, is lacking.
METHODS
METHODS
We are conducting a cluster-randomized trial nested within the Community-Based Chronic Disease Care Lesotho (ComBaCaL) cohort study (NCT05596773) using the trial within cohort (TwiC) design to assess the effectiveness of a VHW-led, CDSS-assisted T2D care model in rural Lesotho. Participants are non-pregnant members of the ComBaCaL cohort study with T2D. The ComBaCaL cohort study is conducted in approximately 100 villages in two rural districts in Lesotho and is managed by trained and supervised VHWs. In intervention villages, VHWs offer a community-based T2D care package including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS to participants who are clinically eligible, as well as treatment support to participants who prefer or clinically require facility-based T2D care. In control clusters, all participants will be referred to a health facility for T2D management. The primary endpoint is the mean glycosylated haemoglobin (HbA1c) 12 months after enrolment. Secondary endpoints include the 10-year risk for cardiovascular events estimated using the World Health Organization risk prediction tool.
DISCUSSION
CONCLUSIONS
The trial was launched on May 13, 2023, and has enrolled 226 participants at the date of submission (October 6, 2023). To our knowledge, the trial is the first to assess task-shifting of T2D care to VHWs at the community level, including the prescription of first-line antidiabetic, lipid-lowering, and antiplatelet medication in sub-Saharan Africa, and will thus provide the missing evidence on the effectiveness of such a T2D care model in this setting. The study is operating within the established Lesotho VHW programme. Similar community health worker programmes which exist across sub-Saharan Africa may benefit from the findings.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05743387. Registered on February 24 2023.
Identifiants
pubmed: 37875943
doi: 10.1186/s13063-023-07729-8
pii: 10.1186/s13063-023-07729-8
pmc: PMC10598965
doi:
Substances chimiques
Hypoglycemic Agents
0
Lipids
0
Banques de données
ClinicalTrials.gov
['NCT05743387']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 323530_207035
Organisme : Direktion für Entwicklung und Zusammenarbeit
ID : 7F-10345.01.01
Organisme : World Diabetes Foundation
ID : WDF20-1778
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
PLoS One. 2017 Mar 1;12(3):e0173160
pubmed: 28249025
J Health Care Poor Underserved. 2008 Nov;19(4):1044-59
pubmed: 19029736
BMJ Glob Health. 2019 Feb 27;4(1):e001258
pubmed: 30899566
Diabetes Res Clin Pract. 2017 Sep;131:70-81
pubmed: 28692830
BMC Med. 2017 Jul 19;15(1):131
pubmed: 28720102
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
Int J Environ Res Public Health. 2020 Aug 13;17(16):
pubmed: 32823510
Lancet Diabetes Endocrinol. 2015 May;3(5):339-55
pubmed: 25819778
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667
pubmed: 28688818
Endocrinol Metab Clin North Am. 2021 Sep;50(3S):e1-e20
pubmed: 34763822
J Trop Med. 2012;2012:349312
pubmed: 23209477
Lancet Diabetes Endocrinol. 2018 Mar;6(3):208-222
pubmed: 29371076
J Diabetes Sci Technol. 2017 Sep;11(5):1015-1027
pubmed: 28560898
PLoS One. 2017 Jul 13;12(7):e0180640
pubmed: 28704405
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Transl Behav Med. 2021 Dec 14;11(12):2144-2154
pubmed: 34424331
Clin Trials. 2012 Feb;9(1):48-55
pubmed: 21948059
Ann Glob Health. 2017 May - Aug;83(3-4):661-675
pubmed: 29221543
AIDS Patient Care STDS. 2012 Mar;26(3):141-7
pubmed: 22304374
Medicine (Baltimore). 2022 Dec 23;101(51):e31943
pubmed: 36595814
Int J Epidemiol. 2017 Feb 1;46(1):96-102
pubmed: 27118559
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Diabetes Res Clin Pract. 2018 Mar;137:10-19
pubmed: 29287838
Mater Sociomed. 2016 Jul 24;28(4):298-302
pubmed: 27698606
PLoS Med. 2022 Apr 15;19(4):e1003964
pubmed: 35427357
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Glob Heart. 2017 Sep;12(3):233-243.e6
pubmed: 27993594
Glob Heart. 2019 Dec;14(4):355-365
pubmed: 31523014
Lancet HIV. 2020 Nov;7(11):e752-e761
pubmed: 33045193
Diabet Med. 2014 Aug;31(8):987-93
pubmed: 24766179
PLOS Glob Public Health. 2022 Jun 15;2(6):e0000599
pubmed: 36962416
Global Health. 2019 Feb 1;15(1):10
pubmed: 30709362
Sci Rep. 2020 Sep 8;10(1):14790
pubmed: 32901098
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
BMJ. 2010 Mar 19;340:c1066
pubmed: 20304934
Diabetes Care. 1997 May;20(5):760-6
pubmed: 9135939
Qual Life Res. 2021 Mar;30(3):647-673
pubmed: 33284428
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
F1000Res. 2021 Jul 5;10:535
pubmed: 35387273
Syst Rev. 2020 Jun 6;9(1):133
pubmed: 32505214
Diabetologia. 2016 Nov;59(11):2298-2307
pubmed: 27531506
Diabetologia. 2010 Jan;53(1):66-9
pubmed: 19841892
CMAJ. 2017 Mar 6;189(9):E341-E364
pubmed: 27799615
Lancet Glob Health. 2019 Oct;7(10):e1332-e1345
pubmed: 31488387
Trans R Soc Trop Med Hyg. 2019 Feb 1;113(2):56-64
pubmed: 30517697
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Afr J Prim Health Care Fam Med. 2020 Feb 20;12(1):e1-e9
pubmed: 32129650
Cad Saude Publica. 2021 Oct 29;37(10):e00287120
pubmed: 34730688